(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 March 2009 (19.03.2009)

PCT

(10) International Publication Number
WO 2009/033704 A1

(51) International Patent Classification:
*C07D 401/04* (2006.01) *A61K 31/4545* (2006.01)
*C07D 493/10* (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:
PCT/EP2008/007551

(22) International Filing Date:
12 September 2008 (12.09.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07116390.1 14 September 2007 (14.09.2007) EP

(71) Applicants *(for all designated States except US)*: **ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.** [US/US]; 1000 U.S. Route 202, Raritan, NJ 08869 (US). **ADDEX PHARMA S.A.** [CH/CH]; 12, chemin des Aulx, CH-1228 Plan-lès-Ouates/Geneva (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **CID-NUNEZ, José Maria** [ES/ES]; Johnson & Johnson, Pharmaceutical Research and Dev, elopment, Division of Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **TRABANCO-SUAREZ, Andrés, Avelino** [ES/ES]; Johnson & Johnson, Pharmaceutical Research and Dev, elopment, Division of Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **MacDONALD, Gregor, James** [GB/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **DUVEY, Guillaume, Albert, Jacques** [FR/CH]; ADDEX Pharma S.A., 12, chemin des Aulx, CH-1228 Plan-lès-Ouates/Geneva (CH). **LÜTJENS, Robert, Johannes** [DE/CH]; ADDEX Pharma S.A., 12, chemin des Aulx, CH-1228 Plan-lès-Ouates/Geneva (CH). **FINN, Terry, Patrick** [GB/CH]; ADDEX Pharma S.A., 12, chemin des Aulx, CH-1228 Plan-lès-Ouates/Geneva (CH).


(74) Agent: **FRANK B. DEHN & CO.**; St Bride's House, 10 Salisbury Square, London EC4Y 8JD (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*

(54) Title: 1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONES




(I)

(57) Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

WO 2009/033704 A1